Diabetes News and Research

Latest Diabetes News and Research

Retailers join to support breast cancer research

This October, retailers nationwide are joining the fight against breast cancer by offering pink ribbon products that benefit research, treatment and education programs at City of Hope, one of the nation’s leading cancer research and treatment centers. From skin and hair care treatments to apparel to office products, consumers can feel good about their purchases and help support lifesaving cancer research.

1 Oct 2009

Membrane-bound Fas ligand is essential for cell death: Researchers

Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also called apoptosis).

1 Oct 2009

Recession impacts health: AOA survey

While the economy begins to show signs of a slow recovery, many consumers continue to struggle with financial challenges, some of which could affect their health. A survey released today by the American Optometric Association (AOA) revealed that 36 percent of Americans say they are limiting their doctor visits because of the recession.

1 Oct 2009

Treatment of gestational diabetes benefits both infant and mother

A National Institutes of Health network study provided the first conclusive evidence that treating pregnant women who have even the mildest form of gestational diabetes can reduce the risk of common birth complications among infants, as well as blood pressure disorders among mothers.

1 Oct 2009

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

1 Oct 2009

Consumption of fish has no major role in protection against heart failure

The consumption of fish has no major role in the prevention of heart failure, according to results from a large prospective population study. The study, which was started in 1990 and involved all men and women over the age of 55 living in a suburb of Rotterdam, found no difference in the risk of developing heart failure between those who did eat fish and those who didn't.

1 Oct 2009

MSN launches new online service to help people manage healthcare decisions

Today, MSN released the beta of My Health Info, a new online service that helps people manage their health information on the Web. My Health Info is a unique service that offers people a variety of tools and widgets to upload, organize and monitor health information stored in their personal Microsoft HealthVault accounts.

1 Oct 2009

Annual campaign to help patients learn about, manage and prevent diabetes

Rite Aid has kicked off its annual campaign on diabetes management by supporting the American Diabetes Association, the leading diabetes voluntary health organization, and dLife, the leading online diabetes resource, in the fight to stop diabetes.

1 Oct 2009

Incyte declares closure of public offering shares

Incyte Corporation today announced the closing of its public offering of 20,700,000 shares of its common stock at a price to the public of $6.75 per share, which includes 2,700,000 shares sold upon exercise by the underwriters of their option to purchase additional shares.

1 Oct 2009

New Magna Pure 96 System from Roche Applied Science

The new MagNA Pure 96 System from Roche Applied Science has been designed and engineered to meet the needs for high throughput laboratories worldwide. Its performance is based on Roche Applied Science’s 10 years experience in the development and application of glass-magnetic-particle based automated nucleic acid purification systems.

1 Oct 2009

Patients with serious mental illness need to be treated for physical and mental health

New research backs up the demand to integrate psychiatric care with primary care services for people with serious mental disorders in Ontario, according to a study published today. "Patients need their care providers to close that gap," says lead author Dr. Russell Callaghan of the Centre for Addiction and Mental Health (CAMH) in Toronto.

1 Oct 2009

Resverlogix RVX-208 exceeds expectations in Phase 1b/2a clinical trial

Resverlogix Corp. announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol.

1 Oct 2009

Poll reveals that 43% of American adults undecided about getting the swine flu vaccine

According to a new Consumer Reports poll, 43 percent of American adults say they're on the fence about getting the swine flu vaccine and just 34 percent of those polled plan on getting the swine flu vaccine when it becomes available. Additionally, a mere 35 percent of parents say they'll definitely have their children vaccinated. The Centers for Disease Control and Prevention recommends that all children over the age of 6 months get the vaccine.

1 Oct 2009

Research study on teens who underwent laparoscopic bypass surgery

According to a recent study of clinical characteristics of teens who underwent laparoscopic Roux-en-Y gastric bypass surgery from 2002 until 2007, doctors may have a much narrower window of opportunity to reverse morbid obesity in teens than previously thought.

30 Sep 2009

‘Sugar Free’ TV show receives significant interest from global television program distributors

Muscle Flex Inc. (PINKSHEETS: MFLI) (www.MuscleFlexInc.com) and Sterling Worldwide Entertainment, LLC (www.SterlingWWE.com), a subsidiary of Visual Industries, Inc., jointly announced today that their television show "Sugar Free," which is currently in pre-production, has received significant expressions of interest from global television program distributors and have engaged the interested media conglomerates in discussions regarding the show.

30 Sep 2009

Strategies to facilitate new, rapid payment system for medical care

A new RAND Corporation study outlines methods that might be used to test a novel payment system for medical care that would provide doctors, hospitals and other health providers a set fee for treating an ailment such as hip replacement surgery.

30 Sep 2009

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

SFC Fluidics, LLC recently announced it has received a contract for approximately $5 million from the Congressionally Directed Medical Research Program for development of a handheld device for rapid diagnosis of traumatic brain injury (TBI). More than 1.5 million Americans suffer head injuries each year, and TBI has become a signature injury for American troops serving in the wars in Iraq and Afghanistan.

30 Sep 2009

Sanofi-aventis announces study results comparing efficacy of Lantus to detemir

Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.

30 Sep 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Plexxikon commences patient dosage in PLX4032 trials for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation occurring in about 50 percent of melanomas and about eight percent of all solid tumors.

30 Sep 2009